PrecivityAD2 is an FDA-cleared blood test for adults age 40 and older with cognitive symptoms undergoing Alzheimer's evaluation. For younger-onset families in 2026, it can support earlier evaluation, but access needs a specialist order, costs vary, and results shape follow-up choices. PrecivityAD2 measures blood markers linked to brain amyloid and combines them into a risk score. Younger-onset Alzheimer's means disease in a person under age 65, according to the Alzheimer's Association, and it can bring work, family, and care-planning strain.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can use the test at age 40 and older?
- What does the score mean?
- Will insurance cover it and what should you check?
- What follow-up questions should younger-onset families ask?
Who can use the test at age 40 and older?
C2N reported via BioSpace that the FDA cleared PrecivityAD2 on Aug. 20, 2026 for symptomatic adults age 40 and older undergoing Alzheimer's evaluation, described as the first FDA-cleared Alzheimer's blood test starting at 40 (FDA clearance announcement via BioSpace). That age threshold matters for younger-onset families because symptoms may start in the 40s or 50s.
It does not make the test an option for memory worries alone. The test must be ordered by a health care professional experienced in cognitive-impairment evaluation and used alongside clinical workup. It is not a standalone diagnosis and not for screening without symptoms. Families should start with a clinician who evaluates thinking, function, medicines, mood, sleep, and other causes.
What does the score mean?
NeurologyLive reported that the test uses high-resolution mass spectrometry to measure plasma amyloid-beta 42/40 and p-tau217 ratios in an Amyloid Probability Score 2 with negative, positive, and likely-positive groups (NeurologyLive report). A negative result lowers the chance of brain amyloid. A positive result raises it and points toward Alzheimer's pathology.
In 1,142 symptomatic adults compared with amyloid PET or spinal fluid testing, the test showed 97.6% positive predictive value and 93.1% negative predictive value. The 17.3% of people in the likely-positive group had 77.3% predictive value. That middle group needs careful follow-up rather than a firm answer.
Will insurance cover it and what should you check?
Clinical Lab Products reported that Anthem Blue Cross and Blue Shield set medical-policy coverage for PrecivityAD2 for eligible members starting Oct. 1, 2026, described as the first U.S. insurer medical-policy coverage for the test (Clinical Lab Products report).
Other coverage remains variable, and Medicare does not cover pre-symptom screening. Younger families should not assume payment. Before blood is drawn, call both the clinic and the insurer. Ask clear benefit questions and write down names, dates, and reference numbers.
- Is PrecivityAD2 covered for this diagnosis code and age?
- Is prior authorization needed, and what records must support it?
- What is the self-pay price, lab fee, draw fee, and billing code?
- If denied, what is the appeal path and timeline?
What follow-up questions should younger-onset families ask?
Ask whether a result is confirmatory or triage for your case. The Alzheimer's Association 2025 blood-biomarker approach sets high accuracy bars for confirmatory use, or a positive triage result needs PET or spinal fluid confirmation. Families should also ask about treatment and trial eligibility, genetic counseling, mood and safety planning, and work accommodations.
Bring a symptom timeline, job impact notes, family history, and medicine list to the visit. Ask who will explain the result, how fast results return, and what happens for each score type. For a likely-positive result, ask what extra testing or referral comes next and what decisions can wait until confirmation.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
